Fierce Biotech1 min read
saveHelus' chemically modified psychedelic hits key goals in phase 3 depression trial
Helus Pharma's oral chemically modified version of psilocybin hit the key goals of a phase 3 study as an adjunctive treatment in major depressive disorder.
comments(0)
5-min edit window · permanent after that